Debra Hussain - Eagle Pharmaceuticals Senior Commercial
| EGRXDelisted Stock | USD 1.99 0.02 1.02% |
Executive
Debra Hussain is Senior Commercial of Eagle Pharmaceuticals
| Age | 56 |
| Phone | 201 326 5300 |
| Web | https://www.eagleus.com |
Eagle Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Eagle Pharmaceuticals currently holds 62.47 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Eagle Pharmaceuticals has a current ratio of 1.74, which is within standard range for the sector. Debt can assist Eagle Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Eagle Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eagle Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eagle to invest in growth at high rates of return. When we think about Eagle Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Craig MD | Alkermes Plc | 56 | |
| MBA MPH | Amphastar P | N/A | |
| Nareg Sagherian | Evolus Inc | N/A | |
| Glenn David | Phibro Animal Health | 52 | |
| Sandra Coombs | Alkermes Plc | N/A | |
| Mary MD | ANI Pharmaceuticals | N/A | |
| MP MBA | Amphastar P | N/A | |
| Krista Davis | ANI Pharmaceuticals | 50 | |
| Samuel Parisi | Alkermes Plc | 49 | |
| Larry Miller | Phibro Animal Health | 60 | |
| Jeffrey Plumer | Evolus Inc | N/A | |
| James Marken | ANI Pharmaceuticals | 61 | |
| Mary Fritz | Prestige Brand Holdings | N/A | |
| Blair Jackson | Alkermes Plc | 51 | |
| Rong MS | Amphastar P | 65 | |
| Ori Gutwerg | ANI Pharmaceuticals | 50 | |
| Antonia Assang | Regencell Bioscience Holdings | N/A | |
| Peter Norman | Alkermes Plc | N/A | |
| YatPui Au | Regencell Bioscience Holdings | 50 | |
| Jessica Novak | Evolus Inc | N/A | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
Management Performance
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 |
Eagle Pharmaceuticals Leadership Team
Elected by the shareholders, the Eagle Pharmaceuticals' board of directors comprises two types of representatives: Eagle Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eagle. The board's role is to monitor Eagle Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eagle Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eagle Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Graves, Independent Director | ||
| Debra Hussain, Senior Commercial | ||
| Gaozhong Zhu, Senior Development | ||
| Reiner Nowak, Exec | ||
| Ryan Debski, General VP | ||
| John Kimmet, Ex Care | ||
| Daniel OConnor, Chief VP | ||
| Steven Ratoff, Independent Director | ||
| Scott Tarriff, CEO and President Director and Member of Executive Committee | ||
| Valentin MD, Senior Development | ||
| Brian Cahill, Chief Officer | ||
| Reed McClung, Executive Development |
Eagle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Eagle Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 82.05 M | ||||
| Shares Outstanding | 12.96 M | ||||
| Shares Owned By Insiders | 12.02 % | ||||
| Shares Owned By Institutions | 76.65 % | ||||
| Number Of Shares Shorted | 350.53 K | ||||
| Price To Earning | 40.52 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Eagle Pink Sheet
If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |